MedDataX Logo

Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL)

NCT00156013 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2017-11-29

Study results available
· View outcomes & findings →

Summary

This research is being done to develop new treatment for non-hodgkin's lymphoma in subjects whose cancer has returned or resisted treatment with chemotherapy. The investigational drug clofarabine is being used in this study. An investigational drug is one that has not been approved by the United States Food and Drug Administration (FDA).

Conditions

  • Lymphoma, B-Cell
  • Lymphoma, Non-Hodgkin

Interventions

DRUG

CLOFARABINE

4 mg/m\^2 days 1-5 of every cycle for a maximum of 6 cycles

Sponsors & Collaborators

  • Genzyme, a Sanofi Company

    collaborator INDUSTRY

  • Oncology Specialists, S.C.

    lead OTHER

Principal Investigators

  • Chadi Nabhan, MD · Oncology Specialists,SC

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2010-04-30
Completion
2010-04-30

Countries

  • United States

Study Locations

Related Clinical Trials

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00156013 on ClinicalTrials.gov